US5278080A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Method for measuring the free fraction of ligands in biological fluids
Assignee: GE Healthcare Ltd
•
Filing: 1993-02-11
•
Granted: 1994-01-11
•
Expires: 2013-02-11
Abstract
Abstract A one-step assay for the free portion of a ligand in a biological sample involves incubating a mixture of the sample with a labelled antibody for the ligand and a ligand analogue which competes with the ligand for binding to the antibody. The assay is characterized by choosing a ligand analogue which has a lower affinity for the antibody than does the ligand. An insolubilised ligand analogue preferably has a binding affinity for the antibody from 0.01% to 10% of that of the ligand. Ligand/ligand analogue pairs exemplified are T4/T3 (Thyroxine/Tri- iodothyronine); Testosterone/etiocholanol; and T3/T2.
Inventors
- 👤 John E. Midgley
- 👤 Christopher P. Sheehan
- 👤 Nicos D. Christofides
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-07 20:22
CPC Classifications
G; G01; G01N; G01N33/00; G01N33/48; G01N33/50; G01N33/74; G01N33/743; G01N33/53; G01N33/575; G01N33/57515; G01N33/78
Claims Analysis
Total Claims: 10
Claim 1
Independent Claim
122 words
A method of assaying the free portion of a ligand selected from the group consisting of thyroid hormones, steroids and cortisol, in a biological fluid sample which also contains a portion of the ligand bound to one or more natural binders, by the user of an antibody for the ligand which antibody is labeled and a differential-binding ligand analogue which competes with the ligand for binding to the antibody, which method comprises incubating the sample with the analogue and the antibody, and observing the extent of binding of the antibody to the analogue, wherein the analogue is chosen to have a binding affinity with the antibody of from 0.01% to 10% of the binding affinity of the free ligand with the antibody.
Claim 2
Independent Claim
122 words
A method of assaying the free portion of a ligand selected from the group consisting of thyroid hormones, steroids and cortisol, in a biological fluid sample which also contains a portion of the ligand bound to one or more natural binders, by the user of an antibody for the ligand which antibody is labeled and a differential-binding ligand analogue which competes with the ligand for binding to the antibody, which method comprises incubating the sample with the analogue and the antibody, and observing the extent of binding of the antibody to the analogue, wherein the analogue is chosen to have a binding affinity with the antibody of from 0.01% to 10% of the binding affinity of the free ligand with the antibody.
Claim 3
Dependent Claim
18 words
The method as claimed in claim 1, wherein the differential-binding ligand analogue is insolubilized prior to the incubation.
Claim 4
Dependent Claim
23 words
The method as claimed in claim 2, wherein the differential-binding ligand analogue is insolubilized by being covalently bound to cellulose or polystyrene particles.
Claim 5
Dependent Claim
14 words
The method as claimed in claim 1, wherein the antibody is labelled with I-125.
Claim 6
Dependent Claim
62 words
The method as claimed in claim 1, wherein the ratio a): b) is between 0.1 and 10, where a) is the affinity constant of the antibody for the analogue times the effective concentration of the analogue, and b) is (the affinity constant of the antibody for the ligand times the concentration of ligand bound to antibody at the end of the incubation.
Claim 7
Dependent Claim
26 words
The method as claimed in claim 1, wherein the ratio of the effective analogue concentration to the antibody concentration is from 10 to 10 5 .
Claim 8
Dependent Claim
33 words
The method as claimed in claim 1, wherein the concentration of analogue binding sites for antibody, and the free ligand concentration, are substantially the same at the beginning and end of the incubation.
Claim 9
Dependent Claim
19 words
The method as claimed in claim 1, wherein the ligand is thyroxxine and the differential-binding ligand analogue is tri-iodothyronine.
Claim 10
Dependent Claim
17 words
The method as claimed in claim 1, wherein the antibody is a monoclonal antibody to the ligand.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1997-01-10 | 1997-07-12 | 1998-01-11 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2001-01-10 | 2001-07-12 | 2002-01-11 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2005-01-10 | 2005-07-12 | 2006-01-11 | $7700.00 | Window Closed / Lapsed |